$IMTX

PERCEPTIVE ADVISORS LLC (EDELMAN JOSEPH) purchased $7.5M of IMTX (indirect holdings)

PERCEPTIVE ADVISORS LLC purchased 863,060 indirectly-held shares of Immatics N.V. (IMTX) at $8.69 ($7.50M total) on 2026-08-26. Filed jointly with EDELMAN JOSEPH (Director) and PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director).

Original reporting
SEC EDGAR · PERCEPTIVE ADVISORS LLC, EDELMAN JOSEPH, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
Published Aug 27, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMTX
Bullish
medium confidence
Mentioned
$IMTX
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMTXBullishMed
01

Why it matters

The disclosed purchase may attract short‑term buying interest, but impact depends on broader biotech trends.

02

Market read

Insider buying is a modest positive catalyst for IMTX, with limited broader market effect.

03

What to watch

Potential upcoming clinical trial milestones that prompted the insider buy.

Relevance 7/10Novelty 6/10Timing: post‑market 2026‑08‑26 filing

Background

Form 4 filings disclose insider transactions; director purchases are monitored for trading signals.

Company-level read

Ticker impact

$IMTXBullishMedium confidence
Context

Director Joseph Edelman bought 863,060 shares at $8.69 each, a $7.5M insider purchase disclosed in a Form 4 filing.

Expected impact

Potential modest price lift as investors view the buy as a bullish signal.

Evidence & confidence

A $7.5M purchase by a director is material for a mid‑cap biotech, indicating insider confidence.

Market effects

May boost sentiment in the biotech sector as insider buying is seen as a vote of confidence.

Limited to U.S. and European biotech investors.

Low; relevance confined to IMTX shareholders and biotech niche.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Immatics N.V.

    Biotech firm developing cancer immunotherapies, ticker IMTX.

  • Joseph Edelman

    Director of Immatics N.V. and purchaser in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMTXHighAI 8/10

Why is Immatics stock climbing today?

Immatics NV (IMTX) stock rose 4.7% to $9.10 in pre-market trading after announcing a $150M share offering. Goldman Sachs reiterated its Buy rating, citing strong analyst consensus and a $17–$19 price target. The company also reported Q2 2026 results, boosting investor confidence. The NASDAQ's rise provided additional support.

$IMTXMedAI 8/10

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Immatics N.V. (NASDAQ: IMTX) reported Q2 2026 results and a SUPRAME Phase 3 update for anzu-cel (IMA203) in advanced melanoma. PFS events are occurring more slowly than modeled, so the company will use a single streamlined final PFS analysis and add ~90 patients to strengthen OS. SUPRAME final PFS topline is expected H1 2027, with BLA submission in 2027. Cash: $448.2M as of June 30, 2026.